In BRCA1 carriers, HRs of breast cancer after RRSO were not significant at 0.96 (95% CI, 0.73 to 1.26), nor were they significant in BRCA2 carriers (HR, 0.65; 95% CI, 0.37 to 1.16). This evidence concerns the gene BRCA1 and breast carcinoma.